News

In celebration of Ophthalmology Times 50th anniversary, we asked leading experts in the field what they see as the biggest innovation in ophthalmology in the last 5 decades.

In celebration of Ophthalmology Times 50th anniversary, we asked leading experts in the field what they see as the biggest innovation in ophthalmology in the last 5 decades.

Lab TRIACTIV is powered by “advanced cationic liposomal technology” for dry eye relief.

Pantheon Vision’s bioengineered corneal implant aims to tackle issues with the success rate of human donated tissue.

Epi-on corneal crosslinking is advancing through innovations like supplemental oxygen, chemical oxygenation, and laser-assisted techniques.

The recall was conducted out of an abundance of caution after the company received reports of complications. The cause of said complications could not be immediately explained.

Aurion is developing AURN001, a clinical-stage allogeneic cell therapy asset, for corneal edema secondary to corneal endothelial disease.

Vision correction has evolved into a continuum of procedures suited for different stages of ocular maturity

Brazilian researchers conducted a study comparing two treatments for postoperative endophthalmitis. They found that pars plana vitrectomy followed by an intravitreal antibiotic injection (PPV + IVAIES) was more effective than using an intravitreal antibiotic injection alone (IVAI).

To create lasting change, ophthalmology must embrace the impact of sponsorship and advocacy—empowering the next generation of leaders with not just knowledge, but the opportunities to excel.

Administered via intravitreal injection, Synthopsin-MCO-010 possesses a promoter to specifically target ON-bipolar cells.

The funding will help fund phase 1 and phase 2 proof-of-concept studies for lead candidates CTX203 and CTX114.

The lens will be available with the Monarch IV manual delivery system in Q2 and the AutonoMe Automated Pre-Loaded Delivery System in Q3.

A combination of canaloplasty and goniotomy provides sustained IOP reduction and decreases medication burden with a strong safety profile, making it a valuable option for glaucoma management.

An AI model for target IOP prediction performs as well as glaucoma specialists, offering a promising tool to enhance glaucoma management, especially for nonspecialists.

The acquisition also includes the ALLY Robotic Cataract Laser Treatment System, LENSAR’s proprietary Streamline software technology and LENSAR legacy laser system.

The trial evaluated sozinibercept (2 mg) every 4 or 8 weeks in combination with aflibercept (2 mg), as per label, every 8 weeks after a loading phase for the treatment of wet AMD.

ZEISS VISULAS Combi is an advanced therapeutic laser workstation offering photodisruption, photocoagulation, and slit lamp technology in a single, comprehensive solution.

UBX1325 is a novel BCL-xL inhibitor designed to eliminate senescent cells in diabetic retinal blood vessels, while leaving healthy ones intact.

The novel nitric oxide-donating bimatoprost eye drop is being clinically developed for the lowering of IOP in patients with open-angle glaucoma or ocular hypertension.

Patients reported that Miebo significantly reduced overall symptoms severity at the primary endpoint of change from baseline in the severity of overall dry eye symptoms at day 7.

The authors noted that while an association between cigarette smoking and TED has been well established, an association between TED and cannabis use has not been determined.

The 9 recipients receive $55,000 in seed money for collaborative projects that target one or more of the foundation’s strategic research goals.

The study findings indicated that lifestyle changes associated with the COVID-19 pandemic were connected to an increase in childhood astigmatisms.

The combined companies will operate under the name Kalaris Therapeutics, Inc. and expects to report initial data from part 1 of its ongoing phase 1 clinical trial of TH103 in treatment-naïve nAMD patients in the second half of 2025.